Breakthrough and Refractory CINV
- 2023 CPG –Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update (open access at Pediatric Blood and Cancer)
- Endorsed by the Children’s Oncology Group (COG) and the Multinational Association of Supportive Care in Cancer (MASCC)
- Archived 2016 CPG – Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy‐induced nausea and vomiting in children with cancer (open access at Pediatric Blood and Cancer)
- Endorsed by the Children’s Oncology Group (COG)
If you have any questions about any of the POGO guidelines, our development processes or guidelines under development, please email:
Paula Robinson, MD, MSc
Senior Manager, Supportive Care and Guidelines
Antibacterial Prophylaxis
Antifungal Prophylaxis
Chemotherapy-Induced Nausea and Vomiting
Acute delayed Phase CINV
Anticipatory CINV
Breakthrough and Refractory CINV
Emetogenicity Classification
Acute and Delayed Phase CINV
Chronic Pain*
Clostridium Difficile Infection
Fatigue
Fertility Preservation*
Mucositis
Ototoxicity
Fever and Neutropenia
Food Restrictions
Platelet Transfusion*
Venous Thromboembolism*
Care Pathways
YOU can be a champion for kids with cancer!
With your help, we will ensure that kids and youth with cancer, their families and survivors of childhood cancer have equitable access to the best care for the best possible outcomes.